Drug (ID: DG01714) and It's Reported Resistant Information
Name
ACY-957/GSK126
Synonyms
ACY-957/GSK126
    Click to Show/Hide
Target . NOUNIPROTAC [1]
Type(s) of Resistant Mechanism of This Drug
  EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Diffuse large B-cell lymphoma [ICD-11: 2A81]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Epigenetic Alteration of DNA, RNA or Protein (EADR) Click to Show/Hide
Key Molecule: Histone-lysine N-methyltransferase EZH2 (EZH2) [1]
Molecule Alteration Missense mutation
p.Y641N (c.1921T>A)
Sensitive Disease Diffuse large B-cell lymphoma [ICD-11: 2A81.0]
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Hela cells Cervix uteri Homo sapiens (Human) CVCL_0030
Experiment for
Molecule Alteration
Chromatin Immunoprecipitation assay; Western blotting analysis
Experiment for
Drug Resistance
Propidium-iodide cell cycle analysis; BrdU-PI cell cycle analysis
Key Molecule: Histone-lysine N-methyltransferase EZH2 (EZH2) [1]
Molecule Alteration Missense mutation
p.Y641N (c.1921T>A)
Sensitive Disease Diffuse large B-cell lymphoma [ICD-11: 2A81.0]
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model Hela cells Cervix uteri Homo sapiens (Human) CVCL_0030
Experiment for
Molecule Alteration
Chromatin Immunoprecipitation assay; Western blotting analysis
Experiment for
Drug Resistance
Propidium-iodide cell cycle analysis; BrdU-PI cell cycle analysis
References
Ref 1 HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphomaOncotarget. 2015 Mar 10;6(7):4863-87. doi: 10.18632/oncotarget.3120.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.